SEARCH

SEARCH BY CITATION

BIBLIOGRAPHY

  • 1
    Cortesina G, De Stefani A, Giovarelli M, et al. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 1988; 62: 24822485.
  • 2
    Tamura T, Sasaki Y, Shinkai T, et al. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy. Cancer Res 1989; 49: 730735.
  • 3
    Cortesina G, De Stefani A, Giovarelli M, et al. Perilymphatic injection of inteleukin-2 in recurrent squamous cell carcinoma of the head and neck. Acta Otorhinolaryngol Ital 1989; 9: 453461.
  • 4
    Ishikawa T, Ikawa T, Eura M, et al. Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumor cells and recombinant interleukin-2. Acta Otolaryngol 1989 107: 346351.
  • 5
    Musiani P, De Campora E, Valitutti S, et al. Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. J Biol Response Mod 1989; 8: 571578.
  • 6
    Stoter G, Goey SH, Eggermont AM, et al. Interleukin-2. The experience of the Rotterdam Cancer Institute, Caniel den Hoed Kliniek. Biotherapy 1990; 2: 261265.
  • 7
    Rivoltini L, Gambacorti-Passerini C, Squadrelli-Saraceno M, et al. In vivo interleukin-2 induced activation of lymphokine-activated killer cells and tumor cytotoxic T cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res 1990; 50: 55515557.
  • 8
    Schantz SP, Clayman G, Racz T, et al. The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1990; 116: 13021308.
  • 9
    Valente G, De Stefani A, Jemma C, et al. Infiltrating leukocyte populations and T-lymphocytes subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin 2. A pathologic and immunophenotypic study. Mod Pathol 1990; 3: 702708.
  • 10
    Cortesina G, De Stefani A, Galeazzi E, et al. The effect of preoperative local interleukin-2 (IL-2) injections in patients with head and neck squamous cell carcinoma. An immunologic study. Acta Otolaryngol 1991; 111: 428433.
  • 11
    Squadrelli-Saraceno M, Rivoltini L, Cantu G, et al. Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2. Tumori 1990; 76: 566571.
  • 12
    Mattijssen V, De Mulder PH, Schornagel JH, et al. Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. J Immunother 1991; 10: 6368.
  • 13
    Cortesina G, DeStefani A, Galeazzi E, et al. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck 1991; 13: 125131.
  • 14
    Melioli G, Margarino G, Scala M, et al. Perilymphatic injections of recombinant inteleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma. Laryngoscope 1992; 102: 572578.
  • 15
    Schantz SP, Dimery I, Lippman SM, et al. A phase II study of inteleukin-2 and interferon-alpha in head and neck cancer. Invest New Drugs 1992; 10: 217223.
  • 16
    Dadian G, Riches PG, Henderson DC, et al. Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol 1993; 29: 2934.
  • 17
    Whiteside TL, Letessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 1993; 53: 56545662.
  • 18
    Cortesina G, De Stefani A, Majore L, et al. Loco-regional treatment with low and high doses of interleukin-2 of head and neck squamous cell carcinoma recurrences. Acta Otorhinolaryngol Ital 1994; 14: 39.
  • 19
    Vlock DR, Snyderman CH, Johnson JT, et al. Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial. J Immunother Emphasis Tumor Immunol 1994; 15: 134139.
  • 20
    Cortesina G, DeStefani A, Galeazzi E, et al. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin-2 injected perilymphatically. Br J Cancer 1994; 69: 572576.
  • 21
    Mattijssen V, De Mulder PH, De Graeff A, et al. Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma. Ann Oncol 1994; 5: 957960.
  • 22
    Valone FH, Gandara DR, Deisseroth AB, et al. Interleukin-2, cisplatinum, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother 1991; 10: 207213.
  • 23
    Mantovani G, Bianchi A, Curreli L, et al. Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL2 in advanced squamous cell carcinoma of the head and neck: a pilot study. Biotherapy 1994; 8: 9198.
  • 24
    Airoldi M, De Stefani A, Marchionatti S, et al. Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. Head Neck 2001; 23: 298304.
  • 25
    Medina JE. The controversial role of BCG in treatment of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1983; 109: 543.
  • 26
    Vogl SE, Schoenfeld DA, Kaplan BH, et al. Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck. Cancer 1982; 50: 22952300.
  • 27
    Vlock DR, Johnson J, Myers E, et al. Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. Head Neck 1991; 13: 1521.
  • 28
    Vlock DR, Andersen J, Kalish LA, et al. Phase II trial of interferon-alpha in locally-recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother 1996; 19: 433436.
  • 29
    Forni G, Giovarelli M, Jemma C, et al. Perilymphatic injections of cytokines: a new tool in active cancer immunotherapy. Experimental rationale and clinical findings. Ann 1st Super Sanita 1990; 26: 397409.
  • 30
    DeStefani A, Valente G, Forni G, et al. Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. J Immunother Emphasis Tumor Immunol 1996; 19: 125133.
  • 31
    Richtsmeier WJ, Koch WM, McGuire WP, et al. Phase I—II study of advanced head and neck squamous cell carcinoma patients treated with recombinant interferon gamma. Arch Otolaryngol Head Neck Surg 1990; 116: 12711277.
  • 32
    Verastegui E, Barrera JL, Zinser J, et al. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer. Int J Immunopharmacol 1997; 19: 619627.
  • 33
    Meneses A, Verastegui E, Barrera JL, et al. Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery. Arch Pathol Lab Med 1998; 122: 447454.
  • 34
    Barrera JL, Verastegui E, Meneses A, et al. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch Otolaryngol Head Neck Surg 2000; 126: 345351.
  • 35
    Mantovani G, Gebbia V, Airoldi M, et al. Neo-adjuvant chemo-(immuno-) therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatinum + 5-fluorouracil (5-FU) with cisplatinum + 5-FU + recombinant interleukin 2. Cancer Immunol Immunother 1998; 47: 149156.
  • 36
    Myers JN, Whiteside TL. Immunotherapy of squamous cell carcinoma of the head and neck. In: MyersE, SuenJ, eds. Cancer of the Head Neck, 3rd ed. Philadelphia: WB Saunders, 1995: 805817.
  • 37
    Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163175.
  • 38
    Shibuya TY, Wei WZ, Zormeier M, et al. Anti-CD3/anti-CD28 MoAb coated suture enhances HNSCC patients immune response. Arch Otolaryngol Head Neck Surg 1999; 25: 12291234.
  • 39
    Shibuya TY, Wei WZ, Zormeier M, et al. Anti-CD3/anti-CD28 bead overcomes suppressed T cell responses in HNSCC patients. Arch Otolaryngol Head Neck Surg 2000; 126: 473479.
  • 40
    Shibuya TY, Nugyen N, McLaren CE, et al. Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res 2002; 8: 745751.
  • 41
    Cortesina G, Sacchi M, Galeazzi E, De Stedfani A. Immunology of head and neck cancer. Perspectives. Head Neck 1993; 15: 7477.
  • 42
    Mickel RA, Kessler DJ, Taylor JM, Lichtenstein A. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Cancer Res 1988; 48: 50175022.
  • 43
    Cortesian G, Sartoris A, DiFortunato V, et al. Natural killer-mediated cytotoxicity in patients with laryngeal carcinoma. Ann Otol Rhinol Laryngol 1984; 93: 189191.
  • 44
    Wang MB, Lichtenstein A, Mickel RA. Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 1991; 105: 517527.
  • 45
    Letessier EM, Sacchi M, Johnson JT, et al. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell Immunol 1990; 130: 446458.
  • 46
    Kessler DJ, Mickel RA, Lichtenstein A. Depressed natural killer cell activity in cervical lymph nodes containing focal metastatic squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1988; 114: 313318.
  • 47
    Heo DS, Whiteside TL, Johnson JT, et al. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes (TIL) from human squamous cell carcinomas of the head and neck. Cancer Res 1987; 47: 63536362.
  • 48
    Horiuchi K, Mishima K, Ohsawa M, et al. Prognostic factors for well-differentiated squamous cell carcinoma in the oral cavity with emphasis on immunohistochemical evaluation. J Surg Oncol 1993; 53: 9296.
  • 49
    Tatake RJ, Krishnan N, Rao RS, et al. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer. Int J Cancer 1989; 43: 560566.
  • 50
    Murali PS, Somasundaram R, Rao RS, et al. Interleukin-2 mediated regulation of mitogen-activated T cell reactivity from different lymphoid sources in patients with squamous cell carcinoma of the oral cavity. J Oral Pathol Med 1989; 18: 327332.
  • 51
    Leess FR, Bredenkamp JK, Lichtenstein A, Mickel RA. Lymphokine-activated killing of autologous and allogenic short-term cultured head and neck carcinomas. Laryngoscope 1989; 99: 12551261.
  • 52
    Ortega IS, Nieto CS, Forcelledo MF. Lymph node response and its relationship to prognosis in carcinomas of the head and neck. Clin Otolaryngol 1987; 12: 241247.
  • 53
    Yasumura S, Weidmann E, Hirabayashi H, et al. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck. Int J Cancer 1994; 57: 297305.
  • 54
    Vitolo D, Letessier EM, Johnson JT, Whiteside TL. Immunologic effector cells in head and neck cancer. J Natl Cancer Inst Monogr 1992; 12: 203208.
  • 55
    Vitolo D, Kanbour A, Johnson JT, et al. In situ hybridization for cytokine gene transcripts in the solid tumor microenvironment. Eur J Cancer 1993; 29: 371377.
  • 56
    Tsukuda M, Mochimatsu I, Sakumoto M, et al. Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas. Biotherapy 1993; 6: 155161.
  • 57
    Yasamura S, Hirabayashi H, Schwartz DR, et al. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res 1993; 53: 14611468.
  • 58
    Young MR, Schmidt-Pak A, Wright MA, et al. Mechanisms of immune suppression in patients with head and neck cancer: presence of immune suppressive CD34+ cells in cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1995; 1: 9561103.
  • 59
    Young MR, Wright MA, Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within head and neck squamous cell carcinoma. J Immunol 1997; 159: 990996.
  • 60
    Young MR, Wright MA, Lozano Y, et al. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996; 67: 333338.
  • 61
    Hiratsuka H, Imamura M, Ishii Y, et al. Immunohistologic detection of lymphocyte subpopulations infiltrating in human oral cancer with special reference to its clinical significance. Cancer 1984; 53: 24562466.
  • 62
    Zeromski J, Szmeja A, Rewer A, Kruk-Zagajewska A. Immunofluorescent assessment of tumor-infiltrating cells in laryngeal carcinoma. Acta Otolaryngol 1986; 102: 325332.
  • 63
    Wolf GT, Hudson JL, Peterson KA, et al. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 1986; 95: 142152.
  • 64
    Bennest SH, Futrell JW, Roth JA, et al. Prognostic significance of histological host response in cancer of the larynx or hypopharynx. Cancer 1971; 28: 12551265.
  • 65
    Hirota J, Vetq E, Osaki T, Ogawa Y. Immunohistologic study of mononuclear cell infiltrates in oral squamous cell carcinomas. Head Neck 1990; 12: 118125.
  • 66
    Snyderman CH, Heo DS, Chen K, et al. T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer. Head Neck 1990; 12: 118125.
  • 67
    Whiteside TL, Heo DS, Chen K. Expansion of tumor-infiltrating lymphocytes from human solid tumors in interleukin-2. In: TruittRL, GaleRP, BortinMM, eds. Progress in Clinical and Biological Research. New York: Alan R Liss, 1987: 213222.
  • 68
    Snyderman CH, Heo DS, Johnson JT, et al. Functional and phenotypic analysis of lymphocytes isolated from tumors and lymph nodes of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1991; 117: 899905.
  • 69
    Nomori H, Watanabe S, Nakajima T, et al. Histiocytes in naso-pharyngeal carcinoma in relations to prognosis. Cancer 1986; 57: 100105.
  • 70
    Neuchrist C, Grasl M, Scheiner O, et al. Squamous cell carcinoma: infiltrating monocyte/macrophage subpopulations express functional mature phenotype. Br J Cancer 1990; 62: 748753.
  • 71
    Horst H-A, Horny H-P. Tumor-infiltrating lymphoreticular cells. Histologic and immunohistologic investigations performed on metastasizing squamous cell carcinomas of the head and neck. Cancer 1991; 68: 23972402.
  • 72
    Cozzolino F, Torcia M, Carossino AM, et al. Characterization of cells from invaded lymph nodes in patients with solid tumors: lymphokine requirement for tumor-specific lymphoid proliferative response. J Exp Med 1987; 166: 303318.
  • 73
    Wustrow TP, Kabelitz D. Interleukin-2 release from lymphocytes of patients with head and neck cancer. Ann Otol Rhinol Laryngol 1987; 98: 179184.
  • 74
    Vinzenz K, Micksche M. Natural cytotoxicity in draining lymph nodes of squamous cell cancer in the maxillofacial region. J Oral Maxillofac Surg 1987; 45: 4247.
  • 75
    Eura M, Maehara T, Ikawa T, Ishikawa T. Suppressor cells in the effector phase of autologous cytotoxic reactions in cancer patients. Cancer Immunol Imunother 1988; 27: 147153.
  • 76
    Letessier EM, Heo DS, Okarama T, et al. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer. Cancer Res 1991; 51: 38913899.
  • 77
    Roubin R, Bekkoucha F, Fondaneche M-C, et al. Lymphoid cells in lymph nodes and peripheral blood of patients with squamous cell carcinoma of the head and neck. J Cancer Res Clin Oncol 1982; 102: 277287.
  • 78
    Schuller DE, Rock RP, Rinehart JJ, Koolemans-Beynen AR. T-lymphocytes as a prognostic indicator in head and neck cancer. Arch Otolaryngol Head Neck Surg 1986; 112: 938941.
  • 79
    Eskinazi DP, Helman J, Ershow AG, et al. Nonspecific immunity and head and neck cancer: blastogenesis reviewed and revisited. Oral Surg Oral Med Oral Pathol 1985; 60: 642647.
  • 80
    Eilber FR, Morton DL, Ketcham AS. Immunologic abnormalities in head and neck cancer. Am J Surg 1974; 128: 534538.
  • 81
    Wanebo HJ, Jun MY, Strong EW, Oettgen H. T-cell deficiency in patients with squamous cell cancer of the head and neck. Am J Surg 1975; 130: 445451.
  • 82
    Mason JM, Kitchens GG, Eastham RJ, Jennings BR. T-lymphocytes and survival of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1977; 103: 233236.
  • 83
    Ryan RE, Neel HB III, Ritts RE. Correlation of preoperative immunologic test results with recurrence in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1980; 88: 5863.
  • 84
    Papenhausen PR, Kukwa A, Croft CB, et al. Cellular immunity in patients with epidermoid cancer of the head and neck. Laryngoscope 1979; 89: 538549.
  • 85
    Eskinazi DP, Perna JJ, Ershow AG, Mihail RC. Depressed PMNC blastogenic response in patients with cancer of the head and neck: a study of IL-2 production, IL-2 consumption, and IL-2 receptor expression. Laryngoscope 1989; 99: 151157.
  • 86
    Wanebo HJ, Jones T, Pace R, et al. Immune restoration with interleukin-2 in patient with squamous cell carcinomas of the head and neck. Am J Surg 1989; 158: 356360.
  • 87
    Hargett S, Wanebo HJ, Pace R, et al. Interleukin-2 production in head and neck cancer patients. Am J Surg 1985; 150: 456460.
  • 88
    Wolf GT, Hudson J, Peterson KA, et al. Interleukin-2 receptor expression in patients with head and neck squamous carcinomas: effects of thymosin a1 in vitro. Arch Otolaryngol Head Neck Surg 1989; 115: 13451349.
  • 89
    Wolf GT, Lovett EJ, Peterson KA, et al. Lymphokine production and lymphocyte subpopulations in patients with head and neck squamous carcinoma. Arch Otolaryngol Head Neck Surg 1984; 110: 731735.
  • 90
    Balaram P, Vasudevan DM. Quantitation of Fc receptor-bearing T-lymphocytes (TG and TM) in oral cancer. Cancer 1983; 52: 18371840.
  • 91
    Johnson JT, Rabin BS, Hirsch B, Thearle PB. T-cell subpopulations in head and neck carcinoma. Arch Otolaryngol Head Neck Surg 1984; 92: 381385.
  • 92
    Dawson DE, Everts EC, Vetto RM, Burger DR. Assessment of immunocompetent cells in patients with head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 1985; 94: 342345.
  • 93
    Strome M, Clark JR, Fried MP, et al. T-cell subsets and natural killer cell function with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1987; 113: 10901093.
  • 94
    Wolf GT, Schmaltz S, Hudson J, et al. Alterations in T-lymphocyte subpopulations in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1987; 113: 12001206.
  • 95
    Schantz SP, Liu FJ. An immunologic profiles of young adults with head and neck cancer. Cancer 1989; 64: 12321237.
  • 96
    Berlinger NT, Tsakraklides V, Pollak K, et al. Immunologic assessment of regional lymph node histology in relation to survival in head and neck carcinoma. Cancer 1976; 37: 697705.
  • 97
    Berlinger NT, Tsakraklides V, Pollak K, et al. Prognostic significance of lymph node histology in patients with squamous cell carcinoma of the larynx, pharynx, or oral cavity. Laryngoscope 1976; 86: 792803.
  • 98
    Ring AH, Sako K, Rao U, et al. Immunologic patterns of regional lymph nodes in squamous cell carcinoma of the floor of the mouth: prognostic significance. Am J Surg 1985; 150: 461465.
  • 99
    Kuss I, Saito T, Johnson JT, Whiteside TL. Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999; 5: 329334.
  • 100
    Brookes GB, Clifford P. Nutritional status and general immune competence in patients with head and neck cancer. JR Soc Med 1981; 74: 132139.
  • 101
    Good RA, Fernandez G, West A. Nutrition, immunity and cancer: a review. I. Influence of protein or protein-calorie malnutrition and zinc deficiency on immunity. Clin Bull 1979; 9: 312.
  • 102
    Hadden JW. Immunology of head and neck cancer. Clin Immunother 1995; 3: 362385.
  • 103
    Coto JA, Hadden EM, Sauro M, et al. Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear kinase C. Proc Natl Acad Sci U S A 1992; 89: 77527756.
  • 104
    Abdulla M, Biorklund A, Mathur A, Walleniusk K. Zinc and copper levels in whole blood and plasma from patients with squamous call carcinoma of head and neck. J Surg Oncol 1979; 12: 107113.
  • 105
    Johnson JT, Rabin BS, Wagner RL. Prostaglandin E2 of the upperaerodigestive tract. Ann Otolaryngol Rhinol Laryngol 1987; 96: 213216.
  • 106
    Snyderman CH, Kaplan I, Milanovich M, et al. Comparison of in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 1994; 111: 189196.
  • 107
    Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983; 3: 295315.
  • 108
    Panje WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981; 107: 658663.
  • 109
    Hirsch B, Johnson JT, Rabin BS, Thearle PB. Immunostimulation of patients with head and neck cancer. Arch Otolaryngol 1983; 109: 298301.
  • 110
    Cross DS, Piatt JL, Juhn SK, et al. Administration of a prostaglandin synthesis inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1992; 118: 526528.
  • 111
    Simons PJ, Oostendorp RA, Tas MP, Drexhage HA. Comparison of retroviral p15E-related factors and interferon alpha in head and neck cancer. Cancer Immunol Immunother 1994; 38: 178184.
  • 112
    Tan IB, Drexhage HA, Mullink R, et al. Immunohistochemical detection of retro viral-P15E-related material in carcinoma of the head and neck. Otolaryngol Head Neck Surg 1987; 96: 251255.
  • 113
    Nelson M, Nelson DS, Spradbrow PB, et al. Successful tumor immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms. Clin Exp Immunol 1985; 61: 109117.
  • 114
    Mann EA, Spiro JD, Chen LL, Kreutzer DL. Cytokine expression by head and neck squamous cell carcinoma. Am J Surg 1992; 164: 567573.
  • 115
    Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas ligand: implications for tumor immune escape. Science 1996; 274: 13631366.
  • 116
    Bennett MW, O'Connell J. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 56695675.
  • 117
    Gratas C, Tohma Y, Barnas C, et al. Up-regulation of Fas ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998; 58: 20572062.
  • 118
    Walker PR, Saas P, Dietrich PY. Role of fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158: 45214524.
  • 119
    Cardi G, Heaney JA, Schned AR, Ernstoff MS. Expression of Fas in tumor infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res 1998; 58: 20782080.
  • 120
    O'Connell J, Bennett MW, O'Sullivan GC, et al. Fas counterattack-the best form of tumor defense? Nat Med 1999; 5: 267268.
  • 121
    Myers JN, Yasamura S, Suminiami Y, et al. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin-4. Clin Cancer Res 1996; 2: 127135.
  • 122
    Byron KA, Varigos GA, Wootton AM. IL-4 production is increased in cigarette smokers. Clin Exp Immunol 1994; 95: 333336.
  • 123
    Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 56135616.
  • 124
    Lai P, Rabinowich H, Crowley-Nowich PA, et al. Alteration in expression and function of signal transducing proteins in tumor associated T and NK cells in patients with ovarian carcinoma. Clin Cancer Res 1996; 2: 161173.
  • 125
    Zea AH, Curti BD, Longo DL, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995; 1: 13271335.
  • 126
    Matsuda M, Petersson M, Lenkei R, et al. Alterations in the signal transducing molecules of T cells and NK cells in colorectal tumor infiltrating gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995; 61: 765772.
  • 127
    Rabinowich H, Reichert TE, Kashii Y, et al. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. J Clin Invest 1998; 101: 25792588.
  • 128
    Mozoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 17951798.
  • 129
    Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal transducing zeta chains in tumor infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53: 56105612.
  • 130
    Reichert TE, Rabinowich H, Johnson JT, Whiteside TL. Mechanisms responsible for signaling and functional defects. J Immunother 1998; 21: 295306.
  • 131
    Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 10961103.
  • 132
    Eisma RJ, Spiro JD, Kreutzer DL. Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck carcinoma. Laryngoscope 1999; 109: 687693.
  • 133
    Rohrich RJ, Trott SA, Love M, et al. Mersilene suture as a vehicle for delivery of growth factors in tendon repair. Plast Reconstr Surg 1999; 104: 17131717.